Skip to main content
FBLG
NASDAQ Life Sciences

Nasdaq Moves to Delist FibroBiologics After Stock Fails $1 Bid Rule

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
10
Price
$0.712
Mkt Cap
$4.329M
52W Low
$0.7
52W High
$14.396
52W Position info
1.7% above low
Off High info
95% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

FBLG is trading near its 52-week low of $0.7 (1.7% above the low) on light trading volume (0.2× avg).

Summary

Nasdaq issued a delisting determination to FibroBiologics on July 22, 2026, after the stock failed to maintain a $1 minimum bid price. The company plans to appeal, but faces suspension on July 31 if unsuccessful.


Key Events · Legal and Risk Events · FBLG

  • Nasdaq Delisting Determination

    Nasdaq notified FibroBiologics on July 22, 2026, that it will delist the company's securities for failing to maintain a $1 minimum bid price over 30 consecutive business days (June 8 – July 21, 2026).

  • No Compliance Period Available

    The company is not eligible for the standard 180-day cure period because it effected a reverse stock split (1-for-20) on March 30, 2026, within the prior one-year period.

  • Imminent Suspension Deadline

    Unless the company requests a hearing by July 29, 2026, trading will be suspended at the opening of business on July 31, 2026.

  • Appeal Planned

    FibroBiologics intends to request a hearing before a Nasdaq Hearings Panel to present a plan to regain compliance, but there is no assurance the appeal will succeed.


Analysis · FBLG · Life Sciences

Nasdaq has determined to delist FibroBiologics after the stock closed below $1 for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period because it completed a reverse stock split in March 2026. Unless an appeal is filed by July 29, trading will be suspended on July 31. The company intends to appeal, but there is no guarantee the panel will grant continued listing. This is a thesis-altering event for a micro-cap biotech already under going-concern warning and actively diluting shareholders through ATM and private placements.

At the time of this filing, FBLG was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.70 to $14.40. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FBLG - Latest Insights

FBLG
Jul 17, 2026, 4:31 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.8349
Real-time Price: $0.7647 info
Change: -$0.0702 (-8%) info
Market Cap: $4.329M info
FBLG
Jul 16, 2026, 4:11 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.8398
Real-time Price: $0.7647 info
Change: -$0.0751 (-9%) info
Market Cap: $4.329M info
FBLG
Jul 09, 2026, 6:05 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.8435
Real-time Price: $0.7647 info
Change: -$0.0788 (-9%) info
Market Cap: $4.329M info
FBLG
Jun 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7809
Real-time Price: $0.7647 info
Change: -$0.0162 (-2%) info
Market Cap: $4.329M info
FBLG
Jun 29, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.7949
Real-time Price: $0.7647 info
Change: -$0.0302 (-4%) info
Market Cap: $4.329M info